Gwendolyn,
Depends on the class of device, but generally Class II, III, and IV it has become more difficult. With the requirement now to have an ISO 13485 certified system + MDSAP this has put a tremendous cost and time restraint on companies trying to enter the Canadian market. Class II, III, and IV devices require as part of the application an ISO 13485 cert + MDSAP (well CMDCAS until 1 Jan 2019) which differs slightly from the EU model which the least burdensome approach is ISO 13485 certification + MDR requirements (Article 10, Annex IX through IX). The United States surprisingly today and at least in the next 3 to 5 years ... unless they change something drastically ... is least burdensome for putting products on the market, initially. An FDA inspection can be done at any time after registering which can still be a significant event, but U.S. does not require ISO 13485 certification prior to marketing the device (... yet :) ).
For a Class I device in any of these markets, it is typically a self-declaration or self-certification. Such as in Canada you apply for a Medical Device Establishment License, but in Canada this can also be very expensive, so large volume is usually needed to justify the cost.
------------------------------
Richard Vincins RAC
Vice President Regulatory Affairs
------------------------------
Original Message:
Sent: 16-Apr-2018 12:00
From: Gwendolyn Lohr
Subject: distribution to canada
My company is in discussion regarding distribution of product to the Canadian market. What differences should be expected from a regulatory perspective to distribute in Canada versus EU and US?
------------------------------
Gwendolyn Lohr
Regulatory & Compliance Specialist
United States
------------------------------